Antonio Llombart-Cussac, MD, PhD, Hospital Arnau de Vilanova, Valencia, Spain, discusses the challenges in implementing circulating tumor DNA (ctDNA) to measure minimal residual disease (MRD) patients with breast cancer. He emphasizes the ongoing learning phase and the various approaches, such as complementing initial tumor assessments with plasma analysis for specific mutations or conducting broad-spectrum mutational status assessments directly on plasma. However, he acknowledges the need for a better understanding of the accuracy of ctDNA in capturing relapse and addressing complexities, especially with methylation. This discussion took place at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.